Biotechnology Company Announces U.S. FDA Grants For Alzheimer's Disease Treatment

Longeveron Inc. (NASDAQ: LGVN), a clinical-stage regenerative medicine biotechnology company specializing in the development of cellular therapies for life-threatening and chronic aging-related conditions, has achieved a goal. The U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Lomecel-B™ for the treatment of mild Alzheimer’s Disease. Lomecel-B™ is a proprietary, scalable, allogeneic cellular investigational therapy currently under evaluation for multiple indications, including Alzheimer’s Disease (Phase 2a completed), Aging-related Frailty (Phase 2b completed), and Hypoplastic Left Heart Syndrome (HLHS) (Phase 2b ongoing). To the best of the company's knowledge, based on publicly available information, Lomecel-B™ is the first cellular therapeutic candidate to receive RMAT designation for Alzheimer’s Disease. $Longeveron (LGVN.US)$